PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > Formulary Search

Search

Reset

BNF Chapter

BNF Paragraph

Please select a BNF Chapter.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A to Z of Drugs : M

Records returned : 151 (on 21 Nov 2024 at 20:04:20).

Drug
Indication
Status
Trust Alignment
Links
Restrictions/Comments
Macitentan
No Information Returned
Macrogol 3350
No Information Returned
Macrogol 4000
No Information Returned
Mafenide
No Information Returned
Magnesium aspartate
No Information Returned
Magnesium carbonate
No Information Returned
Magnesium chloride
No Information Returned
Magnesium citrate
No Information Returned
Magnesium glycerophosphate
No Information Returned
01.06.04
Magnesium hydroxide
Constipation
Green
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Magnesium lactate
No Information Returned
Magnesium orotate
No Information Returned
Magnesium oxide
No Information Returned
Magnesium sulfate
No Information Returned
Magnesium sulphate
No Information Returned
01.01.01
Magnesium trisilicate
Gastro protection
Green
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Malathion
No Information Returned
Maltodextrin
No Information Returned
Mandelic acid
No Information Returned
02.02.05
03.07.00
Mannitol
Cerebral oedema
Red
Formulations :
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Maprotiline hydrochloride
No Information Returned
Maraviroc
No Information Returned
Mazindol
No Information Returned
Measles, mumps and rubella vaccine
No Information Returned
Mebendazole
No Information Returned
01.02.00
Mebeverine hydrochloride
Muscle spasm
Green
Formulations :
  • Suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Suspension not licensed in under 10 years. Tablets not licensed in children.
01.02.00
Mebeverine hydrochloride
Muscle spasm
Green
Formulations :
  • Capsules (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Capsules not licensed in children.
Mebeverine hydrochloride compound preparations
No Information Returned
Mecasermin
No Information Returned
Meclozine hydrochloride
No Information Returned
Mecobalamin
No Information Returned
Mecysteine hydrochloride
No Information Returned
Medicated stockings
No Information Returned
06.04.01
Medroxyprogesterone acetate
Menopausal disorders
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
10mg tablets for adjunctive progestogen therapy
2nd line for endometrial protection in women who have abnormal bleeding on other HRT.
06.04.01
Medroxyprogesterone acetate
Transgender Health - adults
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
10.01.01
Mefenamic acid
Dysmenorrhoea
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.01
Mefenamic acid
Menorrhagia
Green
Formulations :
  • Capsules
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
10.01.01
Mefenamic acid
Pain & inflammation - musculoskeletal
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Important
See separate entry for use in menorrhagia and dysmenorrhoea.
10.01.01
Mefenamic acid
Menorrhagia
Non Formulary
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Consider alternative therapy if a liquid formulation is required.
10.01.01
Mefenamic acid
Dysmenorrhoea
Non Formulary
Formulations :
  • Oral suspension
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Consider alternative therapy if a liquid formulation is required.
Mefloquine hydrochloride
No Information Returned
Megestrol acetate
No Information Returned
04.01.01
Melatonin
Parkinson's disease
Blue
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Rapid eye movement disorder.
Generic 2mg MR tablets.
04.01.01
Melatonin
Jet lag disorder
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
10.01.01
Meloxicam
Pain & inflammation - musculoskeletal
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Not a preferred NSAID, limited place in therapy. ASPH - rheumatology only.
Melperone hydrochloride
No Information Returned
Melphalan
No Information Returned
04.11.00
Memantine hydrochloride
Multiple sclerosis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
Menadiol sodium phosphate
No Information Returned
Meningococcal A + C + W135 + Y vaccine
No Information Returned
Meningococcal A + C vaccine
No Information Returned
Meningococcal B vaccine
No Information Returned
Meningococcal C vaccine
No Information Returned
Menotrophin
No Information Returned
Menthol
No Information Returned
Mepacrine hydrochloride
No Information Returned
Mepenzolate bromide
No Information Returned
Mepivacaine hydrochloride
No Information Returned
Mepolizumab
No Information Returned
Meprobamate
No Information Returned
Meptazinol
No Information Returned
04.07.02
Meptazinol hydrochloride
Pain
Red
Formulations :
  • Intramuscular injection (IM)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Obstetric analgesia
04.07.02
Meptazinol hydrochloride
Pain
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Tablets - Not for chronic or acute, non-malignant pain. Intramuscular injection used in obstetric pain.
Mepyramine maleate
No Information Returned
Mercaptamine
No Information Returned
Mercaptamine hydrochloride
No Information Returned
08.01.03
08.02.01
Mercaptopurine
Inflammatory bowel disease
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Un
Important
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
08.01.03
08.02.01
Mercaptopurine
Neurology indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
08.01.03
08.02.01
Mercaptopurine
Hepatology Indications
Amber
Formulations :
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Tablets and oral suspension are NOT bioequivalent. Do not confuse with mercaptamine (similar name).
05.01.02
05.01.07
Meropenem
Bacterial infection
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Restricted Antimicrobial - requires Microbiology Specialist Approval.
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand.: Octasa or Salofalk gastro resistant tablets (or Salofalk granules) are 1st line for new patients Asacol tablets are non-formulary
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand: Octasa, Salofalk, Pentasa
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Mezevant XL - Reserve for patients with a high pill burden.
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Granules (slow release)
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Preferred
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand: Salofalk granules are a 1st-line option for new patients. Pentasa modified-release tablets and granules for patients who require upper GI release.
01.05.01
Mesalazine
Inflammatory bowel disease
Green (see narrative)
Formulations :
  • Enema
  • Foam enema
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Prescribe by brand: Pentasa / Salofalk enema
01.05.01
Mesalazine
Inflammatory bowel disease
Non Formulary
Formulations :
  • Gastro-resistant tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Ulcerative colitis only. GP may initiate following diagnosis or advice from specialist. Refer to the Ulcerative Colitis pathway.
Asacol 400mg gastro resitsant tablets have been discontinued. The 800mg tablets are non-formulary.
Mesalazine (Systemic)
No Information Returned
Mesna
No Information Returned
Mesterolone
No Information Returned
Mesuximide
No Information Returned
02.07.02
Metaraminol
Hypotension
Red
Formulations :
  • Intravenous injection (IV)
  • Intravenous infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Metformin hydrochloride
No Information Returned
Metformin hydrochloride/pioglitazone
No Information Returned
Metformin hydrochloride/rosiglitazone
No Information Returned
Metformin hydrochloride/sitagliptin
No Information Returned
Metformin hydrochloride/vildagliptin
No Information Returned
Methadone hydrochloride
No Information Returned
05.01.13
Methenamine hippurate
Urinary Tract Infection (UTIs)
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Methionine
No Information Returned
Methocarbamol
No Information Returned
01.05.03
10.01.03
13.05.03
Methotrexate
Rheumatology indications
Amber
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
WEEKLY dosing.
01.05.03
10.01.03
13.05.03
Methotrexate
Rheumatology indications
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
WEEKLY dosing.
2.5mg tablets ONLY. DO NOT PRESCRIBE OR SUPPLY 10mg tablets
01.05.03
10.01.03
13.05.03
Methotrexate
Respiratory disease indications
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
WEEKLY dosing. Only 2.5mg tablets to be prescribed. DO NOT prescribe or supply 10mg tablets
01.05.03
10.01.03
13.05.03
Methotrexate
Dermatology indications
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Weekly dosing. Tablets - only to prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets
01.05.03
10.01.03
13.05.03
Methotrexate
Neurology indications
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets. WEEKLY dosing.
01.05.03
10.01.03
13.05.03
Methotrexate
Uveitis
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
WEEKLY dosing. Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
01.05.03
10.01.03
13.05.03
Methotrexate
Scleritis
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
WEEKLY dosing. Tablets - only prescribe as 2.5mg. DO NOT prescribe or supply 10mg tablets.
01.05.03
10.01.03
13.05.03
Methotrexate
Inflammatory bowel disease
Amber
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
DO NOT prescribe or supply 10mg tablets. WEEKLY dose frequency. Advise patients to carry the patient alert card / book
Methoxamine hydrochloride
No Information Returned
Methoxsalen
No Information Returned
Methoxy polyethylene glycol-epoetin beta
No Information Returned
Methyl nicotinate
No Information Returned
Methyl salicylate
No Information Returned
Methyl salicylate/levomenthol
No Information Returned
Methyl-5-aminolevulinate
No Information Returned
Methylcellulose
No Information Returned
02.05.02
Methyldopa
Hypertension in pregnancy
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NICE
Important
Primary care prescribing on specialist recommendation.
01.06.06
Methylnaltrexone bromide
Constipation
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
For opioid-induced constipation in terminally ill patients when response to other laxatives is inadequate
RSCH Palliative Care Team only
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Adults
Amber
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Un
Important
18mg, 27mg, 36mg, 54mg: Prescribe by brand - use the branded-generic with the lowest acquisition cost
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Adults
Amber
Formulations :
  • Immediate release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Un
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Adults
Amber
Formulations :
  • Modified release capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Un
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Modified release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
Prescribe by brand. Xaggitin XL, Xenidate XL and Delomsart are the locally agreed brands.
04.04.00
Methylphenidate hydrochloride
Attention Deficit Hyperactivity Disorder (ADHD) - Children 6-17yrs
Amber
Formulations :
  • Immediate release tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Important
Prescribe immediate release tablets generically
Methylprednisolone
No Information Returned
Methylprednisolone aceponate
No Information Returned
10.01.02
Methylprednisolone acetate
Soft tissue and joint disorders
Green
Formulations :
  • Intra-articular injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
06.03.02
11.04.01
Methylprednisolone sodium succinate
Ocular surgery
Red
Formulations :
  • Intra-ocular injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
10.01.02
Methylprednisolone with lidocaine
Soft tissue and joint disorders
Green
Formulations :
  • Intra-articular injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Methyltestosterone
No Information Returned
Methysergide
No Information Returned
Metipranolol
No Information Returned
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Un
Important
2nd line treatment option. Should not be prescribed for longer than 5 days.
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting (pregnancy)
Green (see narrative)
Formulations :
  • Oral solution
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Un
Important
2nd line treatment option. Should not be prescribed for longer than 5 days.
An option in patients with swallowing difficulties.
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting (chemotherapy induced)
Blue
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
On request from the specialist / Cancer Centre
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
04.06.00
Metoclopramide hydrochloride
Nausea and vomiting (post operative)
Red
Formulations :
  • Injection
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.02.01
Metolazone
Oedema
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
The licensed (Xaqua) and unlicensed (Zaroxolyn) tablets have different bioavailabilities. These products are not interchangable=Prescribe by Brand
Prescribing in primary care on recommendation of specialist team only.
02.02.01
Metolazone
Heart failure
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
SA
Important
Initiation by specialist. The licensed (Xaqua) and unlicensed (Zaroxolyn) tablets have different bioavailabilities. These products are not interchangable=Prescribe by Brand
02.02.01
Metolazone
Hypertension
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
02.04.00
Metoprolol tartrate
Arrhythmias
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.04.00
Metoprolol tartrate
Angina
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
02.04.00
Metoprolol tartrate
Hypertension
Green (see narrative)
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
Step 4 of the hypertension pathway. Bisoprolol / atenolol are the preferred, cardio-selective beta blockers for hypertension.
02.04.00
Metoprolol tartrate
Arrhythmias
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Metoprolol tartrate with diuretic
No Information Returned
Metreleptin
No Information Returned
05.01.11
07.02.02
13.10.01
Metronidazole
Bacterial vaginosis
Green
Formulations :
  • Vaginal gel
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Refer to local antimicrobial guidelines. Oral metronidazole is as effective as topical treatment and is more cost-effective.
05.01.11
07.02.02
13.10.01
Metronidazole
Bacterial vaginosis
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Refer to local antimicrobial guidelines. Oral metronidazole is as effective as topical treatment and is more cost-effective.
05.01.11
07.02.02
13.10.01
Metronidazole
Bacterial infection
Green
Formulations :
  • Oral solution
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Follow local guidelines on the use of antimicrobials.
05.01.11
07.02.02
13.10.01
Metronidazole
Bacterial infection
Red
Formulations :
  • Infusion
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Follow local guidelines on the use of antimicrobials
05.01.11
07.02.02
13.10.01
Metronidazole
Bacterial infection
Red
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Follow local guidelines on the use of antimicrobials
Metyrapone
No Information Returned
02.03.02
10.02.02
Mexiletine hydrochloride
Myotonia
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
NHSE
BlueTeq
NICE
02.03.02
10.02.02
Mexiletine hydrochloride
Arrhythmias
Red
Formulations :
  • Capsules
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Namuscla brand is non-preferred for this indication
Mianserin hydrochloride
No Information Returned
05.02.04
Micafungin
Fungal infection
Red
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Miconazole
No Information Returned
Miconazole nitrate
No Information Returned
Midazolam hydrochloride
No Information Returned
04.08.02
Midazolam hydrochloride (Buccolam)
Status epilepticus
Blue
Formulations :
  • Pre-filled oral syringe
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
CD
SA
NICE
Important
Preferred
Prescribe by BRAND. Buccolam is currently the preferred, lower-cost in patients over 3 months of age
04.08.02
Midazolam hydrochloride (Buccolam)
Status epilepticus
Red
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Un
Important
Unlicensed preparations / specials have a Red traffic light status - not for prescribing in primary care.
04.08.02
Midazolam hydrochloride (Buccolam)
Status epilepticus
Red
Formulations :
  • Liquid
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
R
U
Important
ASPH Paediatrics only - (high-cost) unlicensed midazolam liquid 12.5mg/5ml sugar free.
Midazolam maleate
No Information Returned
04.08.02
Midazolam maleate (Epistatus)
Status epilepticus
Blue
Formulations :
  • Pre-filled oral syringe
ASPH
RSFT
SASH
SABP
Primary Care
BNF NICE SPC
CD
SA
NICE
Important
Prescribe by BRAND (Epistatus). However, Buccolam is currently the preferred, lower-cost in patients over 3 months of age
04.08.02
Midazolam maleate (Epistatus)
Status epilepticus
Red
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
Un
Important
Unlicensed preparations / specials have a Red traffic light status - not for prescribing in primary care.
04.08.02
Midazolam maleate (Epistatus)
Status epilepticus
Red
Formulations :
  • Liquid
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
R
U
Important
ASPH Paediatrics only - (high-cost) unlicensed midazolam liquid 12.5mg/5ml sugar free.
02.07.02
Midodrine hydrochloride
Orthostatic hypotension
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
Postural hypotension in Parkinson's disease. Specialist team initiation and supply for at least 1 month before transfer of prescribing to primary care.
Midostaurin
No Information Returned
07.01.02
Mifepristone
Termination of pregnancy
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
R
Important
Restricted to use by Gynaecology and Obstetrics departments only
Mifepristone/misoprostol
No Information Returned
Migalastat
No Information Returned
Miglustat
No Information Returned
04.07.04
Migraleve
Migraine (acute)
Non Formulary
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
NFD1
02.01.02
Milrinone lactate
Heart failure
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Un
Important
Restricted use: ITU only at SASH Consultants only at RSCH
02.01.02
Milrinone lactate
Heart failure (children)
Red
Formulations :
  • Injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
ASPH restricted to paediatrics. Off-label
Minocycline hydrochloride
No Information Returned
Minoxidil
No Information Returned
07.04.02
Mirabegron
Overactive bladder (adults)
Green (see narrative)
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
R
Important
Solifenacin is 1st line. Mirabegron for use when antimuscarinics are contraindicated, patients with CNS adverse effects or patients requiring a more potent treatment.
Mirtazapine
No Information Returned
01.03.04
07.01.01
Misoprostol
Termination of pregnancy
Red
Formulations :
  • Vaginal tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
R
Important
Restricted to use by Gynaecology and Obstetrics departments only
01.03.04
07.01.01
Misoprostol
Benign gastric or duodenal ulcer
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
01.03.04
07.01.01
Misoprostol
NSAID induced peptic ulcer
Non Formulary
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Misoprostol (Gynaecology)
No Information Returned
08.01.02
Mitomycin
Glaucoma surgery
Red
Formulations :
  • Eye drops (preservative free)
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Unlicensed cytotoxic. Ophthalmology only
0.02% eye drops.
08.01.02
Mitomycin
Glaucoma surgery
Red
Formulations :
  • Subconjunctival injection
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
U
Important
Unlicensed cytotoxic. Ophthalmology only
Mitotane
No Information Returned
Mitoxantrone
No Information Returned
Mivacurium chloride
No Information Returned
03.04.01
Mizolastine
Allergic rhinitis
Non Formulary
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
NFD1
04.03.02
Moclobemide
Depression
Blue
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
Important
Initiation and stabilisation by specialist for a minimum of 6 months before transfer of prescribing to primary care.
04.04.00
Modafinil
Narcolepsy
Amber
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Important
Pregnancy safety warnings.
04.04.00
Modafinil
Multiple sclerosis
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
SA
Un
Important
Safety in pregnancy warnings.
04.04.00
Modafinil
Shift work sleep disorder
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Pregnancy safety warnings.
04.04.00
Modafinil
Sleep apnoea
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Pregnancy safety warnings.
04.04.00
Modafinil
Hypersomnia
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Pregnancy safety warnings.
Moexipril hydrochloride
No Information Returned
Molgramostim
No Information Returned
05.03.06
Molnupiravir
Covid-19
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
05.03.06
Molnupiravir
Covid-19
See narrative
Formulations :
  • Not Specified
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Mometasone furoate
No Information Returned
Mometasone furoate/olopatadine hydrochloride
No Information Returned
Mometasone/glycopyrronium/indacaterol
No Information Returned
Monobasic potassium phosphate
No Information Returned
Montelukast
No Information Returned
Morphine hydrochloride
No Information Returned
01.04.02
04.07.02
Morphine (Opium Tincture)
Diarrhoea
Non Formulary
Formulations :
  • Oral drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
CD
04.07.02
Morphine sulfate
Pain
Green (see narrative)
Formulations :
  • Capsules (slow release)
  • Granules (slow release)
  • Tablets (slow release)
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
Prescribe modified-release preparations by brand - refer to local guidelines for preferred brands. Zomorph capsules (12-hourly) can be opened for administration in patients unable to swallow the capsules.
04.07.02
Morphine sulfate
Pain
Green (see narrative)
Formulations :
  • Immediate release tablets
  • Oral solution
  • Oro-dispersible
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
Orodispersible tablets are a cost-effective alternative to oral solution. Reserve oral solution and orodispersible tablets for patients in whom a solid dose form is not suitable.
04.07.02
Morphine sulfate
Pain
Red
Formulations :
  • Injection
  • Solution for infusion
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Important
See separate listing for palliative care
04.07.02
Morphine sulfate
Pain
Non Formulary
Formulations :
  • Suppositories
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF SPC
CD
Morphine tartrate and cyclizine tartrate
No Information Returned
05.01.12
11.03.01
Moxifloxacin
Bacterial infection
Red
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
R
SA
Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines or specialist microbiology recommendation.
05.01.12
11.03.01
Moxifloxacin
Bacterial eye infection
Red
Formulations :
  • Eye drops
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Important
SASH: Bacterial conjunctivitis (2nd line or 1st line if severe), Bacterial keratitis (OFF LABEL), Post-op Endophthalmitis (OFF LABEL)
Moxifloxacin hydrochloride
No Information Returned
Moxisylyte hydrochloride
No Information Returned
02.05.02
Moxonidine
Hypertension
Green
Formulations :
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
Guidelines BNF NICE SPC
NICE
Important
ASPH restrict use to cardiology only.
Mupirocin
No Information Returned
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Rheumatology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Uveitis
Amber
Formulations :
  • Capsules
  • Gastro-resistant tablets
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Scleritis
Amber
Formulations :
  • Capsules
  • Gastro-resistant tablets
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Gastroenterology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Haematology Indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Hepatology Indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Oral disease indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Renal indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Respiratory disease indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Dermatology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically
01.05.03
08.02.01
10.01.03
11.04.02
13.05.03
Mycophenolate mofetil
Neurology indications
Amber
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
ASPH
RSFT
SASH
SABP
Primary Care
BNF SPC
Un
Important
Prescribe generically (except in transplant indications)
Mycophenolic sodium
No Information Returned
 

For information about the icons and status values within this site, please refer to the keys below.

Icon/Links Key

NFD1
Non formulary
NFD2
Not assessed for formulary status. Apply to APC / DTC before use.
CD
Controlled drug. Prescribing and/or storage requirements may apply
R
Restrictions apply
SA
Safety Alert
U
Unlicensed - no UK marketing license in place
Un
Off-label use. Not licensed for this indication.
NHSE
Treatment commissioned by NHS England
CDF
CDF
ICB
Treatment commissioned by the ICB
BlueTeq
BlueTeq form to be completed
NICE
NICE

Traffic Light Status Key

Red
Specialist ONLY drugs - treatment initiated and continued by specialist clinicians
Amber
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement
Green
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.
Black
Now referred to as "Non Formulary" but some BLACK drugs remain pending review. Not recommended for use in any health setting across Surrey and NW Sussex health economy.
Amber Star
Now referred to as "Blue" but some Amber Star drugs remain pending review. Prescribing initiated and stabliised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green (see narrative)
GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.
Non Formulary
Not recommended for use in any health setting across Surrey and NW Sussex health economy. (Formerly BLACK traffic light status)
See Below
Please add a description.
N/A
Please add a description.
Blue
Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.
Green - Black
Now referred to as "Do not initiate in new patients" but some GREEN/BLACK drugs remain pending review. These drugs are NOT for new initiations (BLACK, (now referred to as Non Formulary)) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required.
See narrative
See narrative - is applied in instances where there may be more than one traffic light status for a drug. This occurs when the traffic light status may differ between specific cohorts of patients e.g. those of childbearing potential and those who are not (in the case of sodium valproate)
Do not initiate in new patients
These drugs are NOT for new initiations (Non Formulary) but prescribing for existing patients may continue (GREEN). Please refer to the narrative on the Drug Profile page for further information if required. (Formerly GREEN/BLACK traffic light status)
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More